Go Pro
→ A new income category is drawing serious money - here's why (From Investors Alley) (Ad)tc pixel Free KLDO Stock Alerts

Kaleido Biosciences (KLDO) Competitors

Kaleido Biosciences logo
$0.0001 0.00 (0.00%)
As of 09:38 AM Eastern
Compare

KLDO vs. MVLA, PRST, KBNT, AISPW, and APCXW

Should you buy Kaleido Biosciences stock or one of its competitors? Kaleido Biosciences's main competitors and comparable companies include Movella (MVLA), Presto Automation (PRST), Kubient (KBNT), Airship AI (AISPW), and AppTech Payments (APCXW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Kaleido Biosciences compare to Movella?

Movella (NASDAQ:MVLA) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap technology companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

40.9% of Movella shares are owned by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are owned by institutional investors. 20.0% of Movella shares are owned by company insiders. Comparatively, 9.0% of Kaleido Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
MovellaN/A N/A N/A
Kaleido Biosciences N/A N/A N/A

Movella has higher earnings, but lower revenue than Kaleido Biosciences. Movella is trading at a lower price-to-earnings ratio than Kaleido Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Movella-$559K-0.02-$220K-$0.62N/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

Movella has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

In the previous week, Movella's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
Movella Neutral
Kaleido Biosciences Neutral

Summary

Movella and Kaleido Biosciences tied by winning 4 of the 8 factors compared between the two stocks.

How does Kaleido Biosciences compare to Presto Automation?

Kaleido Biosciences (NASDAQ:KLDO) and Presto Automation (NASDAQ:PRST) are both small-cap technology companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Presto Automation has higher revenue and earnings than Kaleido Biosciences. Kaleido Biosciences is trading at a lower price-to-earnings ratio than Presto Automation, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A
Presto Automation$19.05M0.00-$34.48M-$1.23N/A

81.6% of Kaleido Biosciences shares are held by institutional investors. Comparatively, 20.9% of Presto Automation shares are held by institutional investors. 9.0% of Kaleido Biosciences shares are held by insiders. Comparatively, 10.0% of Presto Automation shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Kaleido BiosciencesN/A N/A N/A
Presto Automation N/A N/A N/A

Kaleido Biosciences has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Presto Automation has a beta of -3.45, meaning that its share price is 445% less volatile than the broader market.

In the previous week, Kaleido Biosciences' average media sentiment score of 0.00 equaled Presto Automation'saverage media sentiment score.

Company Overall Sentiment
Kaleido Biosciences Neutral
Presto Automation Neutral

Summary

Presto Automation beats Kaleido Biosciences on 4 of the 7 factors compared between the two stocks.

How does Kaleido Biosciences compare to Kubient?

Kubient (NASDAQ:KBNT) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap technology companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Company Net Margins Return on Equity Return on Assets
KubientN/A N/A N/A
Kaleido Biosciences N/A N/A N/A

Kubient has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

13.9% of Kubient shares are owned by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are owned by institutional investors. 22.3% of Kubient shares are owned by company insiders. Comparatively, 9.0% of Kaleido Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kubient has higher revenue and earnings than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kubient$1.17M0.00-$13.62MN/AN/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

In the previous week, Kubient's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
Kubient Neutral
Kaleido Biosciences Neutral

Summary

Kubient beats Kaleido Biosciences on 4 of the 6 factors compared between the two stocks.

How does Kaleido Biosciences compare to Airship AI?

Airship AI (NASDAQ:AISPW) and Kaleido Biosciences (NASDAQ:KLDO) are both technology companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

81.6% of Kaleido Biosciences shares are owned by institutional investors. 9.0% of Kaleido Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Airship AIN/A N/A N/A
Kaleido Biosciences N/A N/A N/A

Airship AI has higher revenue and earnings than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Airship AI$18.15MN/AN/AN/AN/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

In the previous week, Airship AI's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
Airship AI Neutral
Kaleido Biosciences Neutral

Summary

Kaleido Biosciences beats Airship AI on 2 of the 3 factors compared between the two stocks.

How does Kaleido Biosciences compare to AppTech Payments?

AppTech Payments (NASDAQ:APCXW) and Kaleido Biosciences (NASDAQ:KLDO) are both technology companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

81.6% of Kaleido Biosciences shares are held by institutional investors. 9.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
AppTech PaymentsN/A N/A N/A
Kaleido Biosciences N/A N/A N/A

In the previous week, AppTech Payments' average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
AppTech Payments Neutral
Kaleido Biosciences Neutral

AppTech Payments has higher earnings, but lower revenue than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AppTech Payments$276KN/AN/AN/AN/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

Summary

Kaleido Biosciences beats AppTech Payments on 3 of the 3 factors compared between the two stocks.

Get Kaleido Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLDO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KLDO vs. The Competition

Export
MetricKaleido BiosciencesSoftware IndustryTechnology SectorNASDAQ Exchange
Market Cap$4K$15.84B$29.84B$12.88B
Dividend YieldN/A3.40%2.73%8.57%
P/E Ratio0.00139.8176.1425.39
Price / Sales0.001,292.50593.3798.81
Price / CashN/A45.8947.3252.27
Price / BookN/A7.399.266.19
Net Income-$95.48M$437.25M$679.28M$349.63M
7 Day PerformanceN/A-1.61%-0.94%-0.08%
1 Month PerformanceN/A0.88%-1.21%0.77%
1 Year PerformanceN/A5.08%187.37%15.42%

Kaleido Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KLDO
Kaleido Biosciences
N/A$0.00
flat		N/AN/A$4K$1.10MN/A80
MVLA
Movella
N/A$0.00
flat		N/A-93.9%$10K-$559KN/A3
PRST
Presto Automation
N/AN/AN/AN/A$10K$19.05MN/A4
KBNT
Kubient
N/AN/AN/AN/A$1K$1.17MN/A40
AISPW
Airship AI
N/A$0.54
+5.4%		N/A-60.8%$0.00$18.15MN/A47

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KLDO) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
Microscopic footage reveals immune cells destroying cancer cells
Time-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...
Market Tactic | Sponsoredtc pixel
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
American retirees will miss THIS. Big Banks just moved in.
Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...
Cedar Gold Group | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel